Cologuard is included in major colorectal
cancer (CRC) screening guidelines and quality measures1-8

Ages 45+

USPSTF and ACS CRC
screening recommendations1,2*†

3 year screening
interval

USPSTF and ACS recommendations following a negative Cologuard result1,2‡

3 years of
credit

Healthcare Effectiveness Data
and Information Set (HEDIS®)3§
Cologuard is a part of the standard of care for CRC screening
  • U.S. Preventive Services Task Force (USPSTF)1
  • American Cancer Society (ACS)2
  • American College of Obstetricians and Gynecologists (ACOG)4
  • Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)5
  • Medicare Advantage Star Rating Program6
  • Electronic Clinical Quality Measure (eCQM)7
  • Health Resources and Services Administration Uniform Data Set (UDS)8
See study results with previously nonadherent patients
*

The USPSTF found adequate evidence that screening patients aged 45 to 49 years provides a moderate benefit in reducing CRC deaths and increasing life-years gained. USPSTF-recommended screening modalities include stool-based tests or direct visualization tests.1

†

The ACS makes a qualified recommendation for screening in patients aged 45 to 49 years, indicating clear evidence of benefit of screening but less certainty about the balance of benefits, harms, and patient preferences. ACS-recommended screening modalities include high-sensitivity stool-based tests or structural (visual) examinations.2

‡

The USPSTF-recommended screening frequency for sDNA-FIT is every 1 to 3 years. The ACS-recommended screening interval for mt-sDNA is every 3 years.1,2

§

sDNA (ie, Cologuard) is one of the methods permitted as part of the National Committee for Quality Assurance's (NCQA) HEDIS® quality measures for colon cancer screening. Third-party guidelines and quality measures do not specifically "endorse" commercial products, and inclusion in same does not imply otherwise. HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).3

References: 1. Davidson KW, Barry MJ, Mangione CM, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(19):1965-1977. 2. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250-281. 3. Healthcare Effectiveness Data and Information Set (HEDIS®) Measurement Year 2022 Volume 2: Technical Update. National Committee for Quality Assurance. Published March 31, 2022. Accessed March 24, 2023. https://www.ncqa.org/wp-content/uploads/2022/03/MY-2022-Vol-2-Technical-Update.pdf 4. ACOG endorsed. The American College of Obstetricians and Gynecologists. Updated 2023. Accessed March 24, 2023. https://www.acog.org/clinical/clinical-guidance/acog-endorsed. 5. Decision memo for screening for colorectal cancer - stool DNA testing (CAG-00440N). Centers for Medicare & Medicaid Services. Published October 9, 2014. Accessed March 24, 2023. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=277 6. Announcement of Calendar Year (CY) 2020 Medicare Advantage capitation rates and Medicare Advantage and Part D payment policies and final call letter. Centers for Medicare & Medicaid Services. Accessed March 24, 2023. https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Downloads/Announcement2020.pdf. 7. Colorectal cancer screening. eQCM for 2023 performance period. Electronic Clinical Quality Improvement Resource Center. Updated August 29, 2022. Accessed Apirl 10, 2023. https://ecqi.healthit.gov/ecqm/ec/2023/cms130v11 8. 2021 uniform data system (UDS) program assistance letter (PAL): uniform data system changes for calendar year 2021; October 21, 2020. US Health Resources and Services Administration (HRSA) Health Center Program. Published February 12, 2020. Accessed March 24, 2023. https://bphc.hrsa.gov/sites/default/files/bphc/data-reporting/2020-uds-approved-pal.pdf